Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLADRIBINE vs AFINITOR DISPERZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Everolimus is an m TOR inhibitor that binds to FKBP-12, forming a complex that inhibits the m TOR serine-threonine kinase, thereby blocking cell cycle progression, angiogenesis, and cell growth.
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
Advanced hormone receptor-positive, HER2-negative breast cancer (postmenopausal women, in combination with exemestane),Advanced neuroendocrine tumors of pancreatic origin (unresectable, locally advanced, or metastatic),Advanced neuroendocrine tumors of gastrointestinal or lung origin (unresectable, locally advanced, or metastatic),Renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery,Subependymal giant cell astrocytoma (SEGA) associated with TSC,Renal cell carcinoma (advanced, after failure of sunitinib or sorafenib),Prevention of organ rejection in renal and cardiac transplant recipients (off-label: liver transplant)
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
10 mg orally once daily for advanced hormone receptor-positive, HER2-negative breast cancer; 10 mg orally once daily for advanced pancreatic neuroendocrine tumors; 10 mg orally once daily for advanced renal cell carcinoma; 7.5 mg orally once daily for subependymal giant cell astrocytoma (SEGA); 5 mg orally once daily for tuberous sclerosis complex (TSC)-associated renal angiomyolipoma.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Terminal half-life is approximately 30 hours (range 28-35 hours) in patients with advanced solid tumors, supporting once-daily dosing.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Everolimus is metabolized primarily by CYP3A4 and is a substrate of P-glycoprotein (P-gp). It is also a moderate inhibitor of CYP3A4 and P-gp.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Primarily fecal (80%) with 22% as unchanged drug; renal excretion <5%.
Approximately 20–30% bound to plasma proteins.
Approximately 74% bound to plasma proteins (mainly albumin).
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Mean apparent volume of distribution is 47 L (approximately 0.6 L/kg), indicating extensive tissue distribution.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
Absolute bioavailability of the tablet formulation is approximately 16% after a high-fat meal; dispersible tablet bioavailability is comparable when taken with food.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
For Cr Cl 30-50 m L/min: no adjustment required. For Cr Cl <30 m L/min: contraindicated or not recommended due to lack of data. No specific GFR-based dose reduction recommended.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Child-Pugh A: reduce dose to 7.5 mg daily. Child-Pugh B: reduce dose to 5 mg daily. Child-Pugh C: contraindicated.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
For SEGA in TSC: weight-based dosing targeting AUC similar to adult 10 mg/day. Initial dose 2.5 mg/m² once daily, titrate to trough concentration 5-15 ng/m L. For TSC-associated renal angiomyolipoma: not established in pediatric patients.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
No specific dose adjustment required based on age alone; monitor renal function and dose adjust per renal/hepatic status. Elderly patients may have increased risk of adverse effects such as stomatitis, infections, and metabolic disturbances.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
There is no FDA black box warning for Afinitor Disperz. However, serious infections, including opportunistic infections, may occur.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Non-infectious pneumonitis (including interstitial lung disease) has been reported; monitor for symptoms and consider interruption or discontinuation.,Increased risk of infections, including opportunistic infections (e.g., Pneumocystis jirovecii, TB); monitor and treat promptly.,Increased serum creatinine and proteinuria may occur; monitor renal function.,Angioedema, including life-threatening cases, can occur, especially in patients taking ACE inhibitors.,Stomatitis and mouth ulcers are common; manage with topical treatments and dose modification.,Impaired wound healing; use with caution perioperatively.,Increased risk of bleeding, especially in patients with renal angiomyolipoma and TSC.,Fetal harm can occur; advise effective contraception during treatment.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
Hypersensitivity to everolimus, sirolimus, or any component of the formulation,Severe hepatic impairment (Child-Pugh class C) (relative contraindication; use with caution in moderate impairment)
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Avoid grapefruit, grapefruit juice, and Seville oranges due to CYP3A4 inhibition. Avoid high-fat meals, as they reduce absorption; take on empty stomach or with light fat-free meal. St. John's wort reduces everolimus levels and should be avoided.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
Pregnancy Category D. Animal studies show embryotoxicity and fetotoxicity at subtherapeutic doses. First trimester: risk of major malformations. Second/third trimester: risk of fetal growth restriction, oligohydramnios, and spontaneous abortion.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential serious adverse reactions in nursing infants (e.g., immunosuppression), breastfeeding is contraindicated during treatment and for 2 weeks after last dose.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may reduce exposure; however, due to teratogenicity, use is not recommended unless benefit outweighs risk. Dose adjustments based on therapeutic drug monitoring are not validated.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
AFINITOR DISPERZ (everolimus) is an m TOR inhibitor; tablets for oral suspension are not interchangeable with regular tablets due to different pharmacokinetics. Monitor for non-infectious pneumonitis, rash, stomatitis, metabolic effects (hyperglycemia, hyperlipidemia), and renal impairment. Dose adjustments required for hepatic impairment and concurrent strong CYP3A4/P-gp inhibitors or inducers. Avoid live vaccines during treatment.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
Take exactly as prescribed; do not crush or chew tablets for oral suspension.,Mix dose with water only, do not mix with juice or other liquids.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any new or worsening shortness of breath, cough, or chest pain immediately.,Use effective non-hormonal contraception during and for 8 weeks after last dose.,Avoid live vaccines and close contact with recently vaccinated individuals.,Monitor for mouth sores; use alcohol-free mouthwash and soft toothbrush.,Do not take St. John's wort or strong CYP3A4/P-gp inhibitors/inducers without consulting doctor.
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLADRIBINE vs AFINITOR DISPERZ, answered by our medical review team.
CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. AFINITOR DISPERZ is a mTOR Inhibitor Antineoplastic that works by Everolimus is an m TOR inhibitor that binds to FKBP-12, forming a complex that inhibits the m TOR serine-threonine kinase, thereby blocking cell cycle progression, angiogenesis, and cell growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLADRIBINE and AFINITOR DISPERZ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. The standard adult dose of AFINITOR DISPERZ is: 10 mg orally once daily for advanced hormone receptor-positive, HER2-negative breast cancer; 10 mg orally once daily for advanced pancreatic neuroendocrine tumors; 10 mg orally once daily for advanced renal cell carcinoma; 7.5 mg orally once daily for subependymal giant cell astrocytoma (SEGA); 5 mg orally once daily for tuberous sclerosis complex (TSC)-associated renal angiomyolipoma.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLADRIBINE and AFINITOR DISPERZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. AFINITOR DISPERZ is classified as Category C. Pregnancy Category D. Animal studies show embryotoxicity and fetotoxicity at subtherapeutic doses. First trimester: risk of major malformations. Second/third trimester: risk of fet. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.